Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Telomerase in bladder cancer: back to a better future?

Theodorescu D, Cech TR.

Eur Urol. 2014 Feb;65(2):370-1. doi: 10.1016/j.eururo.2013.10.019. Epub 2013 Oct 28. No abstract available.

PMID:
24184027
2.

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst CD, Platt FM, Knowles MA.

Eur Urol. 2014 Feb;65(2):367-9. doi: 10.1016/j.eururo.2013.08.057. Epub 2013 Sep 3. No abstract available.

PMID:
24035680
4.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.

Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7.

PMID:
24018021
5.

Re: TERT Promoter Mutations and Telomerase Reactivation in Urothelial Cancer.

Atala A.

J Urol. 2015 Sep;194(3):848. doi: 10.1016/j.juro.2015.06.021. Epub 2015 Jun 12. No abstract available.

PMID:
26292896
6.

Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.

Vail E, Zheng X, Zhou M, Yang X, Fallon JT, Epstein JI, Zhong M.

Ann Diagn Pathol. 2015 Oct;19(5):301-5. doi: 10.1016/j.anndiagpath.2015.06.007. Epub 2015 Jun 16.

PMID:
26239299
7.

The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.

Li C, Wu S, Wang H, Bi X, Yang Z, Du Y, He L, Cai Z, Wang J, Fan Z.

Oncotarget. 2015 Aug 14;6(23):19542-51.

8.

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.

Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR.

Science. 2015 Feb 27;347(6225):1006-10. doi: 10.1126/science.1260200. Epub 2015 Feb 5.

9.

[THE SOMATIC MUTATIONS AND ABERRANT METHYLATION AS POTENTIAL GENETIC MARKERS OF URINARY BLADDER CANCER].

Mikhailenko DS, Kushlinskii NE.

Klin Lab Diagn. 2016 Feb;61(2):78-83. Review. Russian.

PMID:
27455559
10.

Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.

Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, Chen C, Lv Z, Tang A, Sun X, Lu J, Li W, Zhou J, Gui Y, Zhou F, Wang D, Cai Z.

Eur Urol. 2014 Feb;65(2):274-7. doi: 10.1016/j.eururo.2013.10.038. Epub 2013 Nov 5.

PMID:
24215939
11.

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.

Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17426-31. doi: 10.1073/pnas.1310522110. Epub 2013 Oct 7.

12.

Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.

Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M.

Cell Cycle. 2013 May 15;12(10):1637-8. doi: 10.4161/cc.24662. Epub 2013 Apr 19. No abstract available.

14.

TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.

Wang K, Liu T, Liu L, Liu J, Liu C, Wang C, Ge N, Ren H, Yan K, Hu S, Björkholm M, Fan Y, Xu D.

Oncotarget. 2014 Apr 15;5(7):1829-36.

15.

Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.

Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M, Zucman-Rossi J.

Hepatology. 2014 Dec;60(6):1983-92. doi: 10.1002/hep.27372. Epub 2014 Oct 27.

PMID:
25123086
16.

High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.

Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT 3rd, Yang XJ, Argani P, Netto GJ, Zhong M.

J Hematol Oncol. 2014 Jul 20;7:47. doi: 10.1186/s13045-014-0047-7.

17.

Usefulness of Multigene Testing: Catching the Train That's Left the Station.

Swisher EM.

JAMA Oncol. 2015 Oct;1(7):951-2. doi: 10.1001/jamaoncol.2015.2699. No abstract available.

PMID:
26270409
18.

Genomic Profiling: Building a Continuum From Knowledge to Care.

Chen HX, Abrams JS.

JAMA Oncol. 2015 Jul;1(4):474-5. doi: 10.1001/jamaoncol.2015.1333. No abstract available.

PMID:
26181257
20.

Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.

Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, Hemminki K, Kumar R.

Int J Cancer. 2015 Oct 1;137(7):1621-9. doi: 10.1002/ijc.29526. Epub 2015 Apr 7.

Supplemental Content

Support Center